Market Overview:
The global ophthalmic therapeutics/drug market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of eye diseases, rising awareness about eye health, and technological advancements in ophthalmic devices. The global ophthalmic therapeutics/drug market is segmented on the basis of type into anti-allergy, anti-VEGF agents, anti-inflammatory, anti-glaucoma, and others. The anti-inflammatory segment is expected to grow at the highest CAGR during the forecast period owing to increasing prevalence of inflammatory eye diseases such as uveitis and iritis. On the basis of application, the global ophthalmic therapeutics/drug market is divided into dry eye syndrome (DES), allergies, glaucoma, infection (bacterial & viral), retinal disorders (age related macular degeneration [AMD], diabetic retinopathy [DRP], retinitis pigmentosa [RP]), and uveitis. The glaucoma segment accounts for a major share of this market due to high incidence rates for glaucoma globally.
Product Definition:
Ophthalmic Therapeutics/Drug is the branch of medicine that deals with the treatment of eye diseases. It is important because it can help to improve vision and quality of life for people who suffer from eye diseases.
Anti-allergy:
Anti-allergy, also known as oral immunotherapy or OIT, is a drug treatment for allergic rhinitis. It works by blocking the action of allergen (substance that causes an allergic response) and helps the patient to recover faster.
Anti-VEGF Agents:
Anti-Vascular Endothelial Growth Factor (VEGF) agents are used in ophthalmic therapeutics to treat macular degeneration, retinitis, and diabetic retinopathy. Macular degeneration is a progressive disease leading to loss of central vision. The major symptoms associated with this condition are Diabetic Retinopathy - gradual damage to the retina resulting in leakage of blood vessels into the eye which may result in blindness if not treated at an early stage.
Application Insights:
The dry eye disease segment held the largest share in the global ophthalmic therapeutics market in 2017. This is due to an increase in the prevalence of dry eye syndrome, which results from a deficiency of tear production or drainage. Dry eyes lead to discomfort and visual impairment, which encourages patients to seek medical attention for treatment.
Dry eyes are caused by various factors including environment, lifestyle habits, hormonal changes and aging along with insufficient blink rate and sensitivity to touch (allergies). The rising number of people affected by allergies is one of the major drivers encouraging manufacturers towards developing new drugs for this condition. For instance, in March 2018 Fotona Biotech launched latanoprost eyewear tablets 0.5 mg/ml for treating allergic conjunctivitis worldwide under brand name Fotofarma 1%.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the local presence of key players, increased R&D activities, and high healthcare expenditure in this region. Moreover, approval of drugs such as Avastin (bevacizumab) for ophthalmic use and Eylea (imilimumab) for non-uveitic glaucoma are also contributing towards market growth. Furthermore, increasing prevalence of uveitis among geriatric population is further fueling regional growth.
Growth Factors:
- Aging population – The global aging population is expected to increase from 600 million in 2010 to more than 2 billion by 2050. This will create a larger pool of patients with age-related eye diseases, such as cataracts, glaucoma, and macular degeneration.
- Increased awareness of eye health – There has been an increased focus on eye health in recent years, due to the growing prevalence of vision problems among all age groups. This has led to greater awareness of the need for ophthalmic treatments and drugs, which is driving demand for these products.
- Rising incidence of eye diseases – The incidence of many common eye diseases is increasing due to factors such as changing lifestyles and increasing exposure to UV radiation. This is leading more people to seek treatment for these conditions, fueling growth in the ophthalmic therapeutics market.
- Advances in technology – New technologies are being developed that are helping improve diagnosis and treatment outcomes for various eye diseases. For example, optical coherence tomography (OCT) is now being used extensively for diagnosing macular degeneration and other retinal disorders .
Scope Of The Report
Report Attributes
Report Details
Report Title
Ophthalmic Therapeutics/Drug Market Research Report
By Type
Anti-allergy, Anti-VEGF Agents, Anti-inflammatory, Anti-glaucoma, Others
By Application
Dry Eye, Allergies, Glaucoma, Infection, Retinal Disorders, Uveitis, Others
By Companies
Alcon, Johnson and Johnson Vision Care, Inc., Bausch & Lomb Incorporated, Novartis AG, Merck Sharp & Dohme Corp., Regeneron Pharmaceuticals Inc., Allergan, Pfizer Inc., Valeant, Bayer AG, Santen Pharmaceuticals Co. Ltd, Genentech, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Ophthalmic Therapeutics/Drug Market Report Segments:
The global Ophthalmic Therapeutics/Drug market is segmented on the basis of:
Types
Anti-allergy, Anti-VEGF Agents, Anti-inflammatory, Anti-glaucoma, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Dry Eye, Allergies, Glaucoma, Infection, Retinal Disorders, Uveitis, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Alcon
- Johnson and Johnson Vision Care, Inc.
- Bausch & Lomb Incorporated
- Novartis AG
- Merck Sharp & Dohme Corp.
- Regeneron Pharmaceuticals Inc.
- Allergan
- Pfizer Inc.
- Valeant
- Bayer AG
- Santen Pharmaceuticals Co. Ltd
- Genentech, Inc.
Highlights of The Ophthalmic Therapeutics/Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anti-allergy
- Anti-VEGF Agents
- Anti-inflammatory
- Anti-glaucoma
- Others
- By Application:
- Dry Eye
- Allergies
- Glaucoma
- Infection
- Retinal Disorders
- Uveitis
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ophthalmic Therapeutics/Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ophthalmic Therapeutics/Drug is a term used to describe medications that are used in the treatment of eye diseases. These medications can be administered by injection, orally, or as a cream or ointment.
Some of the key players operating in the ophthalmic therapeutics/drug market are Alcon, Johnson and Johnson Vision Care, Inc., Bausch & Lomb Incorporated, Novartis AG, Merck Sharp & Dohme Corp., Regeneron Pharmaceuticals Inc., Allergan, Pfizer Inc., Valeant, Bayer AG, Santen Pharmaceuticals Co. Ltd, Genentech, Inc..
The ophthalmic therapeutics/drug market is expected to grow at a compound annual growth rate of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Ophthalmic Therapeutics/Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Ophthalmic Therapeutics/Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Ophthalmic Therapeutics/Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Ophthalmic Therapeutics/Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Ophthalmic Therapeutics/Drug Market Size & Forecast, 2018-2028
4.5.1 Ophthalmic Therapeutics/Drug Market Size and Y-o-Y Growth
4.5.2 Ophthalmic Therapeutics/Drug Market Absolute $ Opportunity
Chapter 5 Global Ophthalmic Therapeutics/Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Ophthalmic Therapeutics/Drug Market Size Forecast by Type
5.2.1 Anti-allergy
5.2.2 Anti-VEGF Agents
5.2.3 Anti-inflammatory
5.2.4 Anti-glaucoma
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Ophthalmic Therapeutics/Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Ophthalmic Therapeutics/Drug Market Size Forecast by Applications
6.2.1 Dry Eye
6.2.2 Allergies
6.2.3 Glaucoma
6.2.4 Infection
6.2.5 Retinal Disorders
6.2.6 Uveitis
6.2.7 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Ophthalmic Therapeutics/Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Ophthalmic Therapeutics/Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Ophthalmic Therapeutics/Drug Analysis and Forecast
9.1 Introduction
9.2 North America Ophthalmic Therapeutics/Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Ophthalmic Therapeutics/Drug Market Size Forecast by Type
9.6.1 Anti-allergy
9.6.2 Anti-VEGF Agents
9.6.3 Anti-inflammatory
9.6.4 Anti-glaucoma
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Ophthalmic Therapeutics/Drug Market Size Forecast by Applications
9.10.1 Dry Eye
9.10.2 Allergies
9.10.3 Glaucoma
9.10.4 Infection
9.10.5 Retinal Disorders
9.10.6 Uveitis
9.10.7 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Ophthalmic Therapeutics/Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Ophthalmic Therapeutics/Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Ophthalmic Therapeutics/Drug Market Size Forecast by Type
10.6.1 Anti-allergy
10.6.2 Anti-VEGF Agents
10.6.3 Anti-inflammatory
10.6.4 Anti-glaucoma
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Ophthalmic Therapeutics/Drug Market Size Forecast by Applications
10.10.1 Dry Eye
10.10.2 Allergies
10.10.3 Glaucoma
10.10.4 Infection
10.10.5 Retinal Disorders
10.10.6 Uveitis
10.10.7 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Ophthalmic Therapeutics/Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Ophthalmic Therapeutics/Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Ophthalmic Therapeutics/Drug Market Size Forecast by Type
11.6.1 Anti-allergy
11.6.2 Anti-VEGF Agents
11.6.3 Anti-inflammatory
11.6.4 Anti-glaucoma
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Ophthalmic Therapeutics/Drug Market Size Forecast by Applications
11.10.1 Dry Eye
11.10.2 Allergies
11.10.3 Glaucoma
11.10.4 Infection
11.10.5 Retinal Disorders
11.10.6 Uveitis
11.10.7 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Ophthalmic Therapeutics/Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Ophthalmic Therapeutics/Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Ophthalmic Therapeutics/Drug Market Size Forecast by Type
12.6.1 Anti-allergy
12.6.2 Anti-VEGF Agents
12.6.3 Anti-inflammatory
12.6.4 Anti-glaucoma
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Ophthalmic Therapeutics/Drug Market Size Forecast by Applications
12.10.1 Dry Eye
12.10.2 Allergies
12.10.3 Glaucoma
12.10.4 Infection
12.10.5 Retinal Disorders
12.10.6 Uveitis
12.10.7 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Ophthalmic Therapeutics/Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Ophthalmic Therapeutics/Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Ophthalmic Therapeutics/Drug Market Size Forecast by Type
13.6.1 Anti-allergy
13.6.2 Anti-VEGF Agents
13.6.3 Anti-inflammatory
13.6.4 Anti-glaucoma
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Ophthalmic Therapeutics/Drug Market Size Forecast by Applications
13.10.1 Dry Eye
13.10.2 Allergies
13.10.3 Glaucoma
13.10.4 Infection
13.10.5 Retinal Disorders
13.10.6 Uveitis
13.10.7 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Ophthalmic Therapeutics/Drug Market: Competitive Dashboard
14.2 Global Ophthalmic Therapeutics/Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Alcon
14.3.2 Johnson and Johnson Vision Care, Inc.
14.3.3 Bausch & Lomb Incorporated
14.3.4 Novartis AG
14.3.5 Merck Sharp & Dohme Corp.
14.3.6 Regeneron Pharmaceuticals Inc.
14.3.7 Allergan
14.3.8 Pfizer Inc.
14.3.9 Valeant
14.3.10 Bayer AG
14.3.11 Santen Pharmaceuticals Co. Ltd
14.3.12 Genentech, Inc.
